Jazz Pharmaceuticals plc — Director's Dealing 2023

Mar 8, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2023-03-03

Reporting Person: Larkin Finbar (SVP, Technical Operations)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-03-03	Ordinary Shares	A	4373	$0.0	Acquired	23854	Direct
2023-03-06	Ordinary Shares	M	1706	$58.72	Acquired	25560	Direct
2023-03-06	Ordinary Shares	S	1706	$143.919	Disposed	23854	Direct
2023-03-07	Ordinary Shares	S	2075	$140.7619	Disposed	21779	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-03-06	Non-Qualified Stock Option (right to buy)	$58.72	M	1706	Disposed	2023-05-02	Ordinary Shares (1706)	Direct

Footnotes

F1: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2023, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years.

F2: Includes 72 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2022.

F3: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

F4: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $140.7578 to $140.7656 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F5: These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vested over four years measured from the grant date, May 3, 2013, with 1/4th vesting on April 9, 2014 and the remainder vesting in 36 equal monthly installments thereafter. The option is fully vested and exercisable as of the date of this Form.